JohansenMDHerrmannJLKremerL.Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus. Nat Rev Microbiol. 2020;18(7):392-407.
2.
van IngenJBoereeMJvan SoolingenDMoutonJW.Resistance mechanisms and drug susceptibility testing on nontuberculosis mycobacteria. Drug Resist Updat. 2012;15:149-161.
3.
LambGSStarkeJR.Mycobacterium abscessus infection in children: a review of current literature. J Pediatric Infect Dis Soc. 2018;7:e131-e144.
4.
van IngenJLooijmansFMirckPDekhuijzenRBoereeMvan SoolingenD. Otomastoiditis caused by Mycobacterium abscessus, the Netherlands. Emerg Infect Dis. 2010;16(1):166-168.
5.
Sédillot-DanielÈVoizardBVallièresÉWoodsOQuintalMC. Chronic suppurative otomastoiditis due to nontuberculous mycobacteria: a case series. Int J Pediatr Otorhinolaryngol. 2020;138:110375.
6.
YehC-FTuT-YWangM-C, et al. Emergence of refractory otomastoiditis due to nontuberculous mycobacteria: institutional experience and review of the literature. Clin Infect Dis. 2016;62:739-745.
7.
MeirMBarkanD.Alternative and experimental therapies of Mycobacterium abscessus infections. Internat J Mol Sci. 2020;21:6793.
8.
DaleyCLIaccarinoJMLangeC, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Clin Infect Dis. 2020;71:e1-36.
9.
WallaceRJJrDukartGBrown-ElliottBAGriffithDEScerpellaEGMarshallB.Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycob-acterium chelonae infections. J Antimicrob Chemother. 2014;69(7):1945-1953.
10.
van WijkFWatervalJvan AerdeK, et al. Successful systemic and topical treatment of Mycobacterium abscessus otomastoiditis. Antimicro Agents Chemother. 2020;64(1):e0120319.
